IL18 and familial pancreatic carcinoma: The combination of IL-18 blocking agent (IL-18 BP) with the hypoxic BXPC-3 conditioned medium (CM) confirmed that 8 inhibits pancreatic cancer angiogenesis by suppressing IL-18 release.